Clinical Trials · NCT06059118
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment
- 50
- Start date
- Oct 2023
- Locations
- 1 site, United States
- Primary endpoint
- PSA response rate at Cycle 1 Day 64